Cheufou Danjouma Housmanou, Welter Stefan, Chalvatzoulis Eleftherios, Christof Daniel, Theegarten Dirk, Stamatis Georgios
Department of Thoracic Surgery and Endoscopy, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.
Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Thorac Cardiovasc Surg. 2014 Oct;62(7):612-5. doi: 10.1055/s-0034-1377060. Epub 2014 Aug 19.
At the time of diagnosis, lung cancer has often metastasized already. Brain metastases, however, are associated with a poor prognosis (median survival of less than 1 year). We evaluated the changes of the median survival after resection of the cerebral metastases and primary non-small cell lung cancer (NSCLC).
Between January 1999 and December 2009, 37 patients (22 men, 15 women; median age: 55.64 years; age range: 38-72 years) underwent surgery for primary NSCLC after craniotomy and removal of the synchronous single brain metastasis. The overall survival was evaluated and risk factors identified.
Mediastinal lymph node involvement was excluded with mediastinoscopy in 26 of the 37 patients. Postoperative N-stage was N0, N1, and N2 in 16 (43%), 10 (27%), and 11 (30%) patients, respectively. Histology was squamous cell carcinoma in 10 (27%), adenocarcinoma in 20 (54%), and large cell carcinoma in 7 (19%). The employed type of resection was anatomical segmentectomy in 6 and lobectomy in 31 patients. The 30-day mortality was 0% and postoperative complications occurred in 12 patients only (32%). The overall 1 and 2 years survival were 62 and 24%, respectively. None of the factors age, sex, tumor histology, primary location of the tumor, type of resection, adjuvant chemotherapy, or nodal status affected survival in the univariate analysis.
The oncologic lung resection of NSCLC after the resection of a single brain metastasis can be implemented without an increased risk of complications or mortality. Despite the stage IV disease, the median survival appears encouraging.
在肺癌确诊时,往往已经发生转移。然而,脑转移与预后不良相关(中位生存期不到1年)。我们评估了脑转移瘤和原发性非小细胞肺癌(NSCLC)切除术后中位生存期的变化。
1999年1月至2009年12月期间,37例患者(22例男性,15例女性;中位年龄:55.64岁;年龄范围:38 - 72岁)在开颅并切除同步发生的单个脑转移瘤后接受了原发性NSCLC手术。评估了总生存期并确定了危险因素。
37例患者中有26例通过纵隔镜检查排除了纵隔淋巴结受累。术后N分期为N0、N1和N2的患者分别有16例(43%)、10例(27%)和11例(30%)。组织学类型为鳞状细胞癌10例(27%)、腺癌20例(54%)、大细胞癌7例(19%)。采用的切除方式为6例行解剖性肺段切除术,31例行肺叶切除术。30天死亡率为0%,仅12例患者(32%)出现术后并发症。1年和2年总生存率分别为62%和24%。在单因素分析中,年龄、性别、肿瘤组织学类型、肿瘤原发部位、切除方式、辅助化疗或淋巴结状态等因素均未影响生存期。
在切除单个脑转移瘤后对NSCLC进行肿瘤性肺切除,不会增加并发症或死亡风险。尽管处于IV期疾病,但中位生存期似乎令人鼓舞。